Bioventus Inc. $BVS Position Lifted by EntryPoint Capital LLC

EntryPoint Capital LLC raised its stake in shares of Bioventus Inc. (NYSE:BVS) by 7.8% during the first quarter, HoldingsChannel reports. The fund owned 28,371 shares of the company’s stock after acquiring an additional 2,048 shares during the quarter. EntryPoint Capital LLC’s holdings in Bioventus were worth $260,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the stock. Wells Fargo & Company MN lifted its position in shares of Bioventus by 32.0% in the 4th quarter. Wells Fargo & Company MN now owns 22,494 shares of the company’s stock worth $236,000 after buying an additional 5,459 shares during the last quarter. Legal & General Group Plc lifted its position in shares of Bioventus by 897.9% in the 4th quarter. Legal & General Group Plc now owns 35,536 shares of the company’s stock worth $373,000 after buying an additional 31,975 shares during the last quarter. Raymond James Financial Inc. bought a new position in shares of Bioventus in the 4th quarter worth about $171,000. Barclays PLC lifted its position in shares of Bioventus by 31.0% in the 4th quarter. Barclays PLC now owns 66,337 shares of the company’s stock worth $696,000 after buying an additional 15,683 shares during the last quarter. Finally, Mariner LLC lifted its position in shares of Bioventus by 2.6% in the 4th quarter. Mariner LLC now owns 146,424 shares of the company’s stock worth $1,537,000 after buying an additional 3,738 shares during the last quarter. 62.94% of the stock is currently owned by institutional investors.

Bioventus Stock Up 7.9%

BVS stock opened at $7.64 on Friday. The company has a quick ratio of 0.99, a current ratio of 1.41 and a debt-to-equity ratio of 1.85. Bioventus Inc. has a fifty-two week low of $5.81 and a fifty-two week high of $14.38. The firm’s 50-day simple moving average is $6.80 and its 200 day simple moving average is $7.81. The stock has a market cap of $631.67 million, a PE ratio of -12.52 and a beta of 0.83.

Analysts Set New Price Targets

BVS has been the topic of a number of recent research reports. Craig Hallum set a $15.00 price target on shares of Bioventus and gave the stock a “buy” rating in a research report on Wednesday, May 7th. Cantor Fitzgerald initiated coverage on shares of Bioventus in a research report on Monday, July 7th. They issued an “overweight” rating and a $12.00 price target on the stock. Three investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $13.75.

Bioventus Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.